Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UPFIRST Study: Upadacitinib for Long-term Remission Maintenance in Rheumatoid Arthritis
jRCT1071240137Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of upadacitinib in rheumatoid arthritis (RA), sponsored by AbbVie Inc. Primary endpoint: Clinical remission at 6 months. Started Mar 2025; status: recruiting.
02
Drugs
upadacitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCT1071240137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1071240137.